LoDoCA: Tolerability of Ritonavir-Boosted Lopinavir- Vs Dolutegravir-Based Antiretroviral Therapy for Children and Adolescents Living with HIV: an Open-Label Randomised Study in Lesotho, Southern Africa

LoDoCA is a prospective cohort study among children and adolescents with HIV in Lesotho, southern Africa who changed from an antiretroviral therapy regimen containing lopinavir to a regimen containing dolutegravir. The study compares treatment satisfaction and previously reported adverse effects of either drug, including neuropsychiatric (sleep, depression) and gastrointestinal outcomes. Sleep is a key focus, as sleep disturbance has previously been reported as an adverse effect of dolutegravir among adults. Thus, sleep is measured by actigraphy (movement-sensing devices worn by participants around their wrist from around bedtime to morning) in addition to questionnaires.